Speciality: Gastroenterology
Description:
Welcome to our podcast. Today, we’re exploring how intestinal organoid secretory profiles could serve as biomarkers for epithelial transport function. Organoids, which are lab-grown mini-organs, closely mimic the structure and function of our intestines. By studying the substances these organoids secrete, scientists can gain valuable insights into how well the intestinal lining transports nutrients and fluids. This approach offers a non-invasive, patient-specific way to assess gut health and diagnose transport disorders. As research advances, organoid secretory profiling could also help evaluate the effectiveness of new treatments for intestinal diseases. In summary, intestinal organoids are opening new doors for personalized medicine and better understanding of gut function.
See More Webinars @ Hidoc Webinars
1.
Three out of ten breast cancers detected between screenings, study finds
2.
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments
3.
Where Did This Very Painful Gluteal Mass Come From?
4.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
5.
Rucaparib Delays Next Lines of Therapy in Ovarian Cancer
1.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
2.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
3.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
4.
Clonal Hematopoiesis Dynamics and Future Hematologic Outcomes
5.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
3.
Evidence-Based Oncology
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Preventing Immune Effector Cell-Associated Neurotoxicity Through Early Neurovascular Biomarker Surveillance
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation